What is the preferred route of estrogen therapy to reduce thrombosis risk?

What is the preferred route of estrogen therapy to reduce thrombosis risk?

• A. Oral
• B. Transdermal
• C. Intramuscular
• D. Subcutaneous

Answer: (B)

Estrogen’s impact on clotting is strongly affected by how it enters the body. Oral estrogen first passes through the liver, which stimulates the production of clotting factors and fibrinogen, elevating the risk of venous thromboembolism. Transdermal estrogen delivers the hormone directly into the bloodstream through the skin, largely bypassing the liver’s first-pass metabolism, so it has a much smaller effect on hepatic clotting-factor production. Because of this, the transdermal route is associated with a lower thrombosis risk and is preferred when the goal is to minimize clotting events. Intramuscular or subcutaneous routes don’t provide the same liver-sparing advantage and aren’t typically chosen for reducing thrombotic risk.

Estrogen’s impact on clotting is strongly affected by how it enters the body. Oral estrogen first passes through the liver, which stimulates the production of clotting factors and fibrinogen, elevating the risk of venous thromboembolism. Transdermal estrogen delivers the hormone directly into the bloodstream through the skin, largely bypassing the liver’s first-pass metabolism, so it has a much smaller effect on hepatic clotting-factor production. Because of this, the transdermal route is associated with a lower thrombosis risk and is preferred when the goal is to minimize clotting events. Intramuscular or subcutaneous routes don’t provide the same liver-sparing advantage and aren’t typically chosen for reducing thrombotic risk.